Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells

Haematologica

Volumn 88, Issue 6, 2003, Pages 694-699

  Martinez Sales, Vicenta ^a   Vila, Virtudes ^a   Réganon, Edelmiro ^a   Oms, Javier Garcia ^a   Aznar, Justo ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Endothelial cells; Enoxaparin; Heparin; Tissue factor pathway inhibitor

Indexed keywords

DECIPAR; ENOXAPARIN; GLYCEROL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROCOAGULANT; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING; CELL CULTURE; CELL LYSATE; CIRCULATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INCUBATION TIME; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANTICOAGULANTS; BLOOD COAGULATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ENOXAPARIN; HEPARIN; HUMANS; LIPOPROTEINS; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

EID: 0037788278     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Broze GJ Jr, Warren LA, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990;29:7630-46.
2. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991;66:67-79.
3. Nemerson Y. Tissue factor: then and now. Thromb Haemost 1995;74:180-4.
4. Levine JD, Harlan JM, Harker LA, Joseph ML, Counts RB. Thrombin-mediated release of factor VIII antigen from human vein endothelial cell in culture. Blood 1982;60:531-4.
5. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2000;86:959-72.
6. Lupu C, Lupu F, Dennehy U, Kakkar W, Scully M. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1995;15:2055-62.
7. Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hanssen TA, Nordoy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscl Throm Vas Biol 1995;15:879-85.
8. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysys 1992;3:439-49.
9. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988;50:803-13.
10. Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991; 64:155-68.
11. Barrowcliffe TW. Low molecular weight heparin(s). Br J Haematol 1995;90:1-7.
12. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-52.
13. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
14. Buckley MM, Sorkin EM. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992;44:465-97.
15. Cadroy Y, Gaspin D, Dupouy D, Lormeau JC, Boneu B, Sié P. Heparin reverses the procoagulant properties of stimulated endothelial cells. Thromb Haemost 1996;75:190-5.
16. Hansen JB, Svensson B, Olsen R, Ezban M, Osteud B. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Throm Haemost 2000;83:937-43.
17. Martinez-Sales V, Gómez-Lechón MJ, Gilabert J. Characteristics of arachidonic acid metabolism of human endothelial cells in culture. Cytotechnology 1990;3:21-9.
18. Westmuckett AD, Lupu C, Roquefeuil S, Krausz T, Kakkar W, Lupu F. Fluid flow induces upregulation of synthesis and release of tissue factor pathway inhibition in vitro. Arterioscler Thromb Vasc Biol. 2000;20:2474-82.
19. Nader HB, Buonassisi V, Colburn P, Dietrich CP. Heparin stimulates the synthesis and modifies the sulfation of heparin sulfate proteoglycan from endothelial cells. J Cell Phisiol 1989;140:305-10.
20. Pinhal MAS, Santos IAN, Silva IF, Dietrich CP, Nader HB. Minimum fragments of heparin molecule are able to produce the accumulation and change of the sulfation pattern of an antithrombotic heparan sulfate from endothelial cells. Thromb Haemostasis 1995;74:1169-74.
21. Mertens G, Cassiman JJ, Van der Berghe H, Vermylen J, David G. Cell surface heparan sulfate proteoglycans from vascular endolthelial cells. Core protein characterization and antithrombin III binding properties. J Biol Chem 1992;267: 20435-43.
22. Grabowski EF, Reininger AJ, Petteruti PG, Tsukurov O, Orkin RW. Shear stress decreases endothelial cell tissue factor activity by augmenting secretion of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2001;21:157-62.
23. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar W, Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999;19:2251-62.
24. Novorty WF, Brown SG, Miletich JP, Rader DJ, Broze GI. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patients samples. Blood 1991;78:387-93.
25. Alban S. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma. Semin Thromb Hemost 2001;27:503-11.
26. Baird SH, Menown IBA, McBride SJ, Trouton TG, Wilson C. Randomized unfractionated heparin following fibrinolytic therapy for acute myocardial infaction. Eur Heart J 2002;23:627-32.
27. Mary V, Wahl F, Uzan A, Stutzmann JM. Enoxaparin in experimental stroke. Neuroprotection and therapeutic window of opportunity. Stroke 2001;32:993-9.
28. Vischer UM, Ingerslev J, Wollheim CB, Mestries JC, Tsakiris DA, Haefell WE, et al. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) levels. Thromb Haemost 1997;77:387-93.
29. Bara L, Bloch MF, Zitoun D, Samama M, Collignon F, Frydman A, et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin and consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993;69:443-52.
30. Beguin S, Mardiguin J, Lindhout T, Hemker HC. The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma. Thromb Haemost 1989;61:30-4.